EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Retrospective Observation of Liver Function Tests in Biologic-Treated Patients with Psoriasis, Psoriatic Arthritis, and/or Hidradenitis Suppurativa

Matthew Bowles, Uche Ndefo, Ashley Lauterbach, Autumn Zuckerman, Prajakta Masurkar, Robert Low, Nicolas Gargurevich, Leena Choi, Katie O’Connell, Chelsea Renfro

SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s870

DOI: 10.25251/2qx7aa11 ↗
AbstractBibliografische Angaben

Abstract

Introduction Although rare cases of elevated liver transaminases occur among patients with psoriasis (PSO), psoriatic arthritis (PsA), and/or hidradenitis suppurativa (HS) receiving biologic or oral targeted systemic treatments, liver function test (LFT) monitoring recommendations are inconsistent. This study aimed to understand real-world LFT monitoring practices among patients with PSO, PsA, and/or HS treated with biologic or oral targeted treatments. We assessed the frequency of LFT abnormalities (outside reference range) and elevations (>3× Upper Limit of Normal [ULN]) and whether these led to treatment modifications. Procedure A real-world retrospective cohort study of adult patients with PSO, PsA, and/or HS initiating a biologic or oral targeted systemic treatment from 01/2021–06/2023 was conducted at an academic medical center in the southeastern US (data source: electronic health record). LFTs were quantified at baseline (within 6 months of prescription) and 12 months post-initiation. LFT assessments at follow-up were analyzed using multivariable negative binomial regression. Results Among 393 patients (median age: 50.1 years; female: 62.3%), most had PSO (86.3%), then PsA (64.4%) and HS (10.9%); 59.8% had >1 diagnosis (typically PSO and PsA). Biologic or oral targeted systemic treatments initiated included tumor necrosis factor inhibitor (TNFi; 45.5%) and phosphodiesterase-4 inhibitor (PDE4i; 27.7%). Overall, 78.6% (309/393) of patients had baseline LFT monitoring; 48.2% (149/309) of patients had ≥1 abnormal (outside of reference range) LFTs, and 0.7% (2/309) of patients had ≥1 elevated LFTs (>3x upper limit of normal [ULN]). During follow-up, 67.7% (n=266) had LFTs (median LFTs [IQR]: 1.0 [1.0–2.0]); 51.9% (138/266) of patients had ≥1 abnormal LFTs, and 1.1% (3/266) of patients had ≥1 elevated LFTs. Additionally, 48.3% (100/207) of individual abnormal LFTs were resolved, with a median (IQR) time to resolution of 151.0 [89.0–204.0] days. Patients with concurrent treatments (incidence rate ratio [IRR]: 1.67; 95% confidence interval [CI]: 1.35–2.06) and patients with comorbidities (IRR: 1.25; 95% CI: 1.00–1.57) had more frequent LFT monitoring. Treatment modifications due to LFT elevations were rare (1/393 patients). Conclusion Most patients initiating a biologic or oral targeted systemic treatment had ≥1 LFTs in the first year of treatment, although LFT elevations and treatment modifications were rare.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →